Therefore, activation of PI3K/AKT/mTOR pathway due to impaired PIK3CA and PTEN genes may play a key role among MOC accounting for the lack of response of HCC patients to sorafenib. The gene discussed is PIK3CA; the disease is hepatocellular carcinoma.